Technology

Industry leaders share perspectives on moving the life sciences industry forward.

Traditionally difficult in pharma, data science recruitment witnessed a sharp drop-off at the beginning of the pandemic, but interest has since bounced back to unexpected levels.

Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.

Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.

Clay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.

Unconventional collaborations between biopharma and tech are starting to take off.

While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.

How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.

Medical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.

In today‘s environment, medical science liaisons (MSLs) must call on digital solutions to make use of the right data and encourage the right conversations to take place.

”Soft skills” are notoriously difficult to teach. For that reason, many trainers are applying state-of-the-art computer simulations to help develop these skills within pharma sales organizations, writes Jeremy Lovelace.

How a large, global biopharma company is leveraging a data-linking strategy to power insight-generation tools and techniques—and supporting customers through their journey with dynamic personalization and modular content.

Leslie Rotz and Todd Parker outline four major steps in the Medical Affairs digital transformation journey.

Digital transformation in medical affairs made a sluggish start, but there is plenty to be optimistic about.

AI-enabled digital therapeutics have helped give new meaning to the term personalized medicine by tailoring not just the treatment itself, but the way that treatment is managed to the individual characteristics of each patient.

Pfizer’s Darren Feenan and Tangent90’s Jan van den Burg talk to Pharm Exec about sharing scientific content with HCPs in an era of accelerated digitalization.

The massive shift to remote work has seen pharma companies increasingly targeted by malicious actors seeking out weaker points across the business ecosystem. But with the right mix of technology and mindset, organizations can prepare against threats in the future.

Current practices leave much to be desired with increasing commercial needs.

Liva Healthcare’s Philipp M. Schäfer talks about the company’s ambitions to drive a positive behavior change in type 2 diabetes.

More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

Companies now have a unique opportunity to rethink their customer engagement strategy and find new techniques to serve healthcare professionals more effectively.

Content generation on pharma companies social media channels started with sharing links to recent publications and conference presentations. But what is the next step? How can the industry evolve from data dissemination to true two-way engagement?

Anita Kawatra discusses advancing clinical and pharmaceutical progress while protecting patient privacy.

Accelerated implementation of AI platforms among pharma sales teams has highlighted the importance of the human factor.

What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?

The next few years will require life science companies to bring consumer-facing digital services to the core of their corporate competence, rather than leaving it at the periphery of their business capabilities.

Computer-based simulations are a great approach to pharmaceutical sales training because they are engaging, realistic and help develop critical skills for a data-driven world, writes Jeremy Lovelace.

Wesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.

Grünenthal‘s Florent Edouard talks about AI‘s “key role in the future of marketing.”